Dr. Reddy’s Laboratories shares in focus on denial of workforce reduction
[hfe_template id='11223']
[ad_1]
Shares of Dr. Reddy’s Laboratories are expected to be in focus in Tuesday’s trading session after the company issued a clarification denying recent media reports about a major workforce cost cut. In an exchange filing, the pharmaceutical major responded to a news article published in Business Standard on April 13, which claimed that Dr. Reddy’s had reduced its workforce costs by 25% amid margin pressures linked to Revlimid. The company categorically denied the claim, stating the news item is “factually incorrect” and that it “categorically denies” both the reported workforce cost reduction and the other assertions made in the article. “This is in reference to Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) regarding a news item published in Business Standard (newspaper/ media) on April 13, 2025, with the heading “DRL trims workforce costs by 25% amid Revlimid-l...